REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31

REGENERON PHARMACEUTICALS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026

$782.04−8.70 (-1.10%)

Close on Oct 19, 2026

Market cap: $82.90B
P/E (TTM): 19.3
Dividend yield: –

REGENERON PHARMACEUTICALS, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31
Revenue	14,343	14,202	13,117	12,173	16,072	8,497	6,558	5,146	5,872	4,860	4,104	2,820	2,105	1,378	446	459	379	238
Cost of Revenue	–	–	–	–	–	–	403	238	203	195	242	129	118	84	4.22	2.09	1.69	0.92
Gross Profit	–	–	–	–	–	–	6,155	4,908	5,670	4,666	3,862	2,691	1,987	1,295	442	457	378	238
Research & Development	5,850	5,132	4,439	3,593	2,860	2,647	2,450	1,469	2,075	2,052	1,621	1,271	860	626	530	489	399	275
Selling, General & Admin	2,700	2,954	2,631	2,116	1,825	1,346	1,342	1,127	1,320	1,178	839	519	346	211	117	65	53	49
Total Costs & Expenses	10,765	10,211	9,070	7,434	7,125	4,921	4,348	2,611	3,793	3,530	2,852	1,996	1,362	921	651	557	453	325
Operating Income	3,578	3,991	4,047	4,739	8,947	3,577	2,210	2,534	2,080	1,331	1,252	824	743	458	-205	-97	-74	-86
Interest Expense	44	55	73	59	57	57	30	28	25	7.20	14	37	46	45	21	9.12	2.34	7.75
Other Non-Operating Income	1,653	789	152	120	379	234	219	19	-1.10	-0.90	-27	-63	-47	-43	-18	-7.00	2.15	9.47
Asset Impairment Charges	–	–	–	–	–	–	–	–	–	–	–	–	0.50	2.80	0	0	–	–
Gain (Loss) on Investments	956	118	-236	–	0	–	0	–	–	–	–	–	–	–	–	-0.29	0.06	-1.31
Pretax Income	5,231	4,780	4,199	4,859	9,326	3,810	2,429	2,554	2,079	1,330	1,225	761	696	414	-223	-104	-72	-77
Income Tax Expense	726	367	246	520	1,251	297	313	109	880	434	589	423	283	-336	-1.13	0	-4.12	2.35
Net Income	4,505	4,413	3,954	4,338	8,075	3,513	2,116	2,444	1,199	896	636	338	414	750	-222	-104	-68	-79
Net Income to Common	–	–	–	–	–	–	–	–	–	–	–	348	424	779	-222	-104	–	–
EPS (Basic)(per share)	43.07	40.90	37.05	40.51	76.40	32.65	19.38	22.65	11.27	8.55	6.17	3.36	4.23	7.92	-2.45	-1.26	-0.85	–
EPS (Diluted)(per share)	41.48	38.34	34.77	38.22	71.97	30.52	18.46	21.29	10.34	7.70	5.52	2.98	3.72	6.75	-2.45	-1.26	-0.85	–
Shares Outstanding (Basic, Weighted)(shares)	105	108	107	107	106	108	109	108	106	105	103	101	98	95	91	83	–	–
Shares Outstanding (Diluted, Weighted)(shares)	109	115	114	114	112	115	115	115	116	116	115	113	111	115	91	83	–	–
EBITDA	4,122	4,474	4,468	5,080	9,233	3,813	2,420	2,683	2,225	1,435	1,327	877	784	495	-174	-78	-60	-75

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: 24.7%
Net margin: 27.9%
Return on equity, FY2025: 14.9%

Financial strength

Current ratio: 3.34
Debt to equity: 0.06
Debt to assets: 4.8%
Cash to current liabilities: 44.4%

Valuation

P/E ratio: 19.3
Price to sales: 5.34
Price to book: 2.61
Dividend yield: –